LU90396I2 - Pariet principeactif: rabeprazole sodique rabeprazole et tout autre de ces sels pharmaceutiquement acceptable - Google Patents

Pariet principeactif: rabeprazole sodique rabeprazole et tout autre de ces sels pharmaceutiquement acceptable

Info

Publication number
LU90396I2
LU90396I2 LU90396C LU90396C LU90396I2 LU 90396 I2 LU90396 I2 LU 90396I2 LU 90396 C LU90396 C LU 90396C LU 90396 C LU90396 C LU 90396C LU 90396 I2 LU90396 I2 LU 90396I2
Authority
LU
Luxembourg
Prior art keywords
group
stands
alkoxy
alkyl
rabeprazole
Prior art date
Application number
LU90396C
Other languages
English (en)
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27283658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90396(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of LU90396I2 publication Critical patent/LU90396I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
LU90396C 1986-11-13 1999-05-07 Pariet principeactif: rabeprazole sodique rabeprazole et tout autre de ces sels pharmaceutiquement acceptable LU90396I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP27053686 1986-11-13
JP2198987 1987-02-02
JP7778487 1987-03-31

Publications (1)

Publication Number Publication Date
LU90396I2 true LU90396I2 (fr) 1999-07-07

Family

ID=27283658

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90396C LU90396I2 (fr) 1986-11-13 1999-05-07 Pariet principeactif: rabeprazole sodique rabeprazole et tout autre de ces sels pharmaceutiquement acceptable

Country Status (18)

Country Link
US (3) US5045552A (fr)
EP (3) EP0268956B2 (fr)
JP (1) JP2544567B2 (fr)
KR (1) KR910003330B1 (fr)
CN (1) CN1018923B (fr)
AT (2) ATE163011T1 (fr)
AU (1) AU594836B2 (fr)
CA (1) CA1265138A (fr)
DE (4) DE3789536T3 (fr)
DK (2) DK171024B1 (fr)
ES (3) ES2112260T3 (fr)
FI (1) FI90544C (fr)
HK (1) HK194296A (fr)
HU (1) HU198475B (fr)
LU (1) LU90396I2 (fr)
NL (1) NL990015I2 (fr)
NO (2) NO170932C (fr)
NZ (1) NZ222488A (fr)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62201884A (ja) * 1986-02-28 1987-09-05 Tokyo Tanabe Co Ltd ベンズイミダゾール誘導体及びその製造法
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
AT391693B (de) * 1988-11-15 1990-11-12 Cl Pharma Verfahren zur herstellung von 3-5-dimethyl-4methoxypyridinderivaten sowie neues zwischenprodukt hierfuer
US5294629A (en) * 1988-11-22 1994-03-15 Meiji Seika Kaisha, Ltd. Benzothiazole and benzimidazole derivatives and antiulcer agent containing the same
SE8804629D0 (sv) * 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
IE64199B1 (en) * 1988-12-22 1995-07-12 Haessle Ab Compound with gastric acid inhibitory effect and process for its preparation
US4965269A (en) * 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
US5049674A (en) * 1989-12-20 1991-09-17 Aktiebolaget Hassle Therapeutically active fluoro substituted benzimidazoles
ES2024357A6 (es) * 1990-12-05 1992-02-16 Genesis Para La Investigacion Procedimiento de obtencion de halohidrato de 2-halometil-3,5-dimetil-4-metoxipiri-dina.
WO1993006097A1 (fr) * 1991-09-20 1993-04-01 Merck & Co., Inc. Nouveau procede de preparation d'agents anti-ulcereux
US5504082A (en) * 1992-06-01 1996-04-02 Yoshitomi Pharmaceutical Industries, Ltd. Pyridine compound and pharmaceutical compostions
DE69302646T2 (de) * 1992-08-21 1996-10-31 Eisai Co Ltd Benzimidazolverbindungen als Antibiotika gegen Campylobacter pylon
EP0683776B1 (fr) * 1993-02-17 1999-04-07 Byk Gulden Lomberg Chemische Fabrik GmbH Heteroarylalkylthiopyridines substituees pour la lutte contre les bacteries helicobacter
SK280159B6 (sk) * 1993-06-29 1999-09-10 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituované aryltioalkyltiopyridíny, spôsob ich
TW280770B (fr) 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
EP0729957A4 (fr) * 1993-10-29 1996-12-27 Yoshitomi Pharmaceutical Compose de pyridine et son utilisation en tant que remede
KR0142815B1 (ko) * 1994-12-02 1998-07-15 정도언 신규한 5-피롤릴-6-할로게노-2피리딜메틸설피닐벤즈이미다졸 유도체
KR0179401B1 (ko) * 1994-02-28 1999-03-20 송택선 신규한 5-피롤릴-2-피리딜메틸설피닐벤즈이미다졸 유도체
HRP960232A2 (en) * 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
KR970032861A (ko) * 1995-12-29 1997-07-22 김준웅 헬리코박터 피로리 제거용 약제 투여방법
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
AU6551198A (en) * 1997-05-30 1998-12-30 Dr. Reddy's Research Foundation Novel benzimidazole derivatives as antiulcer agents, process for their preparation and pharmaceutical compositions containing them
WO1999004816A1 (fr) 1997-07-25 1999-02-04 Byk Gulden Lomberg Chemische Fabrik Gmbh Inhibiteur de la pompe a protons en combinaison therapeutique avec des substances antibacteriennes
JP3459407B2 (ja) * 1997-10-14 2003-10-20 エーザイ株式会社 安定剤としてグリシンを含む製薬学的製剤
US7230014B1 (en) * 1997-10-14 2007-06-12 Eisai Co., Ltd. Pharmaceutical formulation comprising glycine as a stabilizer
US6861448B2 (en) 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
CA2317439A1 (fr) 1998-01-14 1999-07-22 Wayne J. Brouillette Procede de synthese et de criblage d'inhibiteurs d'enzyme synthetase nad bacterienne, composes a base de cette enzyme et procedes de traitement des infections bacteriennes et microbiennes au moyen d'inhibiteurs de ladite enzyme
DE19815634A1 (de) * 1998-04-07 1999-10-14 Bayer Ag Verfahren zur Herstellung von 3-Methoxy-1-propanol
AU3870599A (en) * 1998-04-30 1999-11-16 Sepracor, Inc. R-rabeprazole compositions and methods
CA2330324A1 (fr) * 1998-04-30 1999-11-04 Sepracor Inc. Compositions a base de s-rabeprazole et procedes
WO2000000474A1 (fr) * 1998-06-26 2000-01-06 Russinsky Limited Blocs constitutifs de pyrimidine utilises comme intermediaires dans la synthese de composes pharmaceutiquement actifs
US6093734A (en) * 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
TR200100431T2 (tr) 1998-08-10 2001-06-21 Partnership Of Michael E. Garst, George Sachs & Jai Moo Proton pompalama önleyici ilaçlar
ATE321538T1 (de) 1998-08-12 2006-04-15 Altana Pharma Ag Orale darreichungsform für pyridin-2- ylmethylsulfinyl-1h-benzimidazole
DE19843413C1 (de) * 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
JP3926936B2 (ja) * 1998-11-16 2007-06-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホキシド誘導体・アセトン錯体およびその製造法
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6362202B1 (en) 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6174902B1 (en) 1999-04-28 2001-01-16 Sepracor Inc. R-rabeprazole compositions and methods
ES2246238T3 (es) 1999-06-07 2006-02-16 Altana Pharma Ag Nueva preparacion y forma de administracion que comprende un inhibidor de las bombas de protones labil en medio acido.
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
AU2001251083A1 (en) 2000-03-31 2001-10-15 Ortho-Mcneil Pharmaceutical, Inc. Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as h3 antagonists
JP2005508830A (ja) * 2000-06-19 2005-04-07 エーザイ株式会社 ピリジン誘導体を用いる方法
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
WO2002026210A2 (fr) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Formulation d'inhibiteur de la pompe à protons
CA2430824C (fr) 2000-12-07 2012-05-08 Altana Pharma Ag Preparation pharmaceutique sous forme de suspension contenant un ingredient actif labile en milieu acide
EP1341524B1 (fr) 2000-12-07 2011-10-19 Nycomed GmbH Preparation pharmaceutique en pate comprenant un ingredient actif labile en milieu acide
US7147869B2 (en) 2000-12-07 2006-12-12 Altana Pharma Ag Rapidly disintegrating tablet comprising an acid-labile active ingredient
NL1018295C2 (nl) * 2001-06-15 2002-12-17 Dsm Nv Werkwijze voor de bereiding van 4-chloor-pyridine-n-oxiden.
CN1243749C (zh) * 2001-09-18 2006-03-01 泽里新药工业株式会社 苯并咪唑衍生物
WO2003063927A2 (fr) * 2001-11-16 2003-08-07 Eisai Co. Ltd Compositions et procedes permettant de traiter les troubles gastro-intestinaux
SE0104295D0 (sv) * 2001-12-18 2001-12-18 Astrazeneca Ab New process
CA2480358A1 (fr) * 2002-03-26 2003-10-09 Dr. Reddy's Laboratories Limited Formes cristallines de rabeprazole sodique
AU2003241464A1 (en) * 2002-05-17 2003-12-02 Eisai Co., Ltd. Compositions and methods using proton pump inhibitors
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
EP1534278A4 (fr) * 2002-08-01 2006-09-06 Nitromed Inc Inhibiteurs nitroses de la pompe a protons, compositions et procedes d'utilisation
AT413538B (de) * 2002-10-01 2006-03-15 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von substituierten pyridin-n-oxid-verbindungen
DE10254167A1 (de) 2002-11-20 2004-06-09 Icon Genetics Ag Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen
ES2383679T3 (es) 2002-12-06 2012-06-25 Nycomed Gmbh Procedimiento para la preparación de (S)-pantoprazol
AR042277A1 (es) 2002-12-06 2005-06-15 Altana Pharma Ag Un procedimiento para la preparacion de sulfinil benzimidazoles opticamente puros
AR046245A1 (es) * 2002-12-16 2005-11-30 Ranbaxy Lab Ltd Sales de calcio de rabeprazol
CA2510849A1 (fr) * 2002-12-19 2004-07-08 Teva Pharmaceutical Industries Ltd Etats solides de sodium de pantoprazole, leurs procedes de preparation et procedes de preparation d'hydrates de sodium de pantoprazole connus
US20060094762A1 (en) * 2003-01-07 2006-05-04 Yatendra Kumar Magnesium salt of imidazole derivative
US20040180935A1 (en) * 2003-02-28 2004-09-16 Dr. Reddy's Laboratories Limited Dr. Reddy's Laboratories Inc. Crystalline form Z of rabeprazole sodium and process for preparation thereof
CA2518999A1 (fr) * 2003-03-12 2004-09-23 Teva Pharmaceutical Industries Ltd Formes solides cristallines et amorphes de pantoprazole et procedes de preparation de ces formes
JP4355703B2 (ja) * 2003-03-13 2009-11-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 歯ぎしりの予防剤または治療剤
EP1607395B1 (fr) 2003-03-24 2011-05-04 Eisai R&D Management Co., Ltd. Procédé de préparation de sel de sodium de rabeprazole amorphe
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
US7524837B2 (en) * 2003-05-12 2009-04-28 Janssen Pharmaceutica N.V. Benzotriazapinone salts and methods for using same
WO2004111029A2 (fr) * 2003-06-10 2004-12-23 Teva Pharmaceutical Industries Ltd. Procede de preparation de benzimidazoles 2-[(pyridinyl)methyl]sulfinyle substitues et nouveau derives chlorures de pantoprazole
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
AU2004264401A1 (en) * 2003-07-15 2005-02-24 Allergan, Inc. Process for preparing isomerically pure prodrugs of proton pump inhibitors
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005020954A2 (fr) * 2003-09-03 2005-03-10 Agi Therapeutics Limited Formulations inhibitrices de pompe a proton, et procedes d'elaboration et d'utilisation correspondantes
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
WO2005039640A1 (fr) * 2003-10-03 2005-05-06 Allergan Inc. Compositions contenant des peptides en trefle et/ou des mucoadhesifs et des promedicaments d'un inhibiteur de pompe a proton
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
EP1716136A1 (fr) 2004-02-11 2006-11-02 Ulkar Kimya Sanayii Ve Ticaret A.S. Pyridine benzimidazole sulphoxides de grande pureté
JP2007523163A (ja) * 2004-02-18 2007-08-16 アラーガン、インコーポレイテッド プロトンポンプインヒビターのプロドラッグの投与のための方法および組成物
AU2005216863A1 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Methods and compositions for the intravenous administration of compounds related to proton pump inhibitors
EP1742630A4 (fr) * 2004-04-16 2010-01-20 Santarus Inc Combinaison d'un inhibiteur de la pompe a protons, d'un agent tampon et d'un agent prokinetique
ES2376466T3 (es) * 2004-05-07 2012-03-14 Nycomed Gmbh Forma de dosificación farmacéutica que comprende peletes, as�? como su procedimiento de fabricación.
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2006003946A1 (fr) * 2004-06-30 2006-01-12 Eisai R & D Management Co., Ltd. Procédé pour produire des précipités de sel dérivé de benzimidazole
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
WO2006013960A1 (fr) * 2004-08-06 2006-02-09 Eisai R & D Management Co., Ltd. Sels de derive de benzimidazole avec des amines et procede de production de ceux-ci
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
WO2006024890A1 (fr) * 2004-08-30 2006-03-09 Apollo International Limited Procede ameliore de preparation de rabeprazole sodique sous forme amorphe
WO2006034632A1 (fr) * 2004-09-30 2006-04-06 Jiangsu Hansen Pharmaceutical Co., Ltd. Nouveau compose prazole et son utilisation
CN100364989C (zh) * 2004-09-30 2008-01-30 江苏豪森药业股份有限公司 拉唑类衍生物及其盐和用途
AU2005306579B2 (en) 2004-11-22 2012-01-19 Immuron Limited Bioactive compositions
CA2606799C (fr) * 2005-02-21 2015-04-28 Cipla Limited Procede de synthese d'inhibiteurs de pompe a protons
AU2006245298A1 (en) * 2005-03-30 2006-11-16 Lupin Limited An improved process for the manufacture of rabeprazole sodium
US7601737B2 (en) 2005-07-26 2009-10-13 Nycomed Gmbh Isotopically substituted proton pump inhibitors
GB0525710D0 (en) * 2005-12-17 2006-01-25 Pliva Hrvatska D O O An improved process for preparing of substituted 2-benzimidazolesulfoxide compounds
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
EP1818331A1 (fr) 2006-02-14 2007-08-15 EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. Procédé pour la préparation de 2-[{4-(3-méthoxypropoxy)-3-méthyl-2-pyridinyl}méthylsulfinyl]-1H-benzimidazole essentiellement exempte d'impurité sulfone
DK2003130T3 (da) * 2006-03-10 2011-12-12 Arigen Pharmaceuticals Inc Nyt pyridinderivat med anti-helicobacter pylori-aktivitet
JP5457830B2 (ja) 2006-04-03 2014-04-02 オディディ，イサ オルガノゾル被膜を含む制御放出送達デバイス
KR100771655B1 (ko) * 2006-04-24 2007-10-30 주식회사 카이로제닉스 라베프라졸 및 그 중간체의 제조방법
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US7786309B2 (en) 2006-06-09 2010-08-31 Apotex Pharmachem Inc. Process for the preparation of esomeprazole and salts thereof
US7863330B2 (en) * 2006-06-14 2011-01-04 Rottapharm S.P.A. Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders
WO2008017020A2 (fr) * 2006-08-03 2008-02-07 Dr. Reddy's Laboratories Limited Procédé de preparation d'inhibiteurs de la pompe à protons
WO2008036201A1 (fr) * 2006-09-19 2008-03-27 Alevium Pharmaceuticals, Inc. Promédicaments d'inhibiteurs de pompes à protons comprenant le groupe fonctionnel 1h-imidazo[4,5-b] pyridine
EP2068841B1 (fr) 2006-10-05 2018-09-26 Santarus, Inc. Nouvelles formulations pour une libération immédiate d'inhibiteurs de pompe à protons et procédés d'utilisation de ces formulations
WO2008047681A1 (fr) * 2006-10-13 2008-04-24 Eisai R & D Management Co., Ltd. Benzimidazole présentant une activité inhibitrice de la sécrétion d'acide gastrique
CA2667682A1 (fr) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprenant des agents d'inhibition de la pompe a protons labiles d'acide, au moins un autre agent pharmaceutiquement actif et leurs procedes d'utilisation
MX2009006638A (es) 2006-12-18 2009-07-02 Arigen Pharmaceuticals Inc Agente para erradicar helicobacter pylori que tiene actividad inhibidora sobre la secrecion de acido gastrico.
ITMI20062449A1 (it) 2006-12-19 2008-06-20 Dipharma Spa Forma cristallina di rabeprazolo sodico
EP2124884B1 (fr) 2006-12-22 2019-07-10 Ironwood Pharmaceuticals, Inc. Compositions contenant des chelateurs d'acide biliaire pour le traitement des troubles oesphagiens
JP2010521453A (ja) * 2007-03-15 2010-06-24 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド 新規プロドラッグ
EP2162449A4 (fr) * 2007-05-25 2011-07-13 Hetero Drugs Ltd Procédé amélioré de preparation de rabéprazole sodique amorphe
US8247568B2 (en) * 2007-06-21 2012-08-21 Matrix Laboratories Ltd Process for the preparation of pure rabeprazole
WO2009010937A1 (fr) * 2007-07-17 2009-01-22 Ranbaxy Laboratories Limited Procédé de préparation de pantoprazole sodique.
CN101497604B (zh) * 2008-01-30 2012-09-26 山东轩竹医药科技有限公司 含有被烷氧乙酰胺基氧基取代的吡啶的苯并咪唑衍生物
CN101497603B (zh) * 2008-01-30 2012-11-07 山东轩竹医药科技有限公司 含有被烷氧烷胺氧基取代的吡啶的苯并咪唑衍生物
SI22806A (sl) * 2008-06-23 2009-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Nove kristalinične oblike natrijevega rabeprazola
BRPI1014314A2 (pt) 2009-04-09 2019-09-24 Arigen Pharmaceuticals Inc derivado de tiopiridina, e, composição farmacêutica.
WO2010134099A1 (fr) 2009-05-21 2010-11-25 Cadila Healthcare Limited Procédé de préparation dans un récipient unique d'oméprazole
WO2011004281A1 (fr) 2009-07-09 2011-01-13 Alembic Limited Procédé pour la préparation d’une forme amorphe de rabéprazole sodium
CN102140099A (zh) 2010-02-02 2011-08-03 山东轩竹医药科技有限公司 新的吡啶衍生物
CA2795056C (fr) * 2010-03-31 2015-03-24 Ranbaxy Laboratories Limited Sels de dexlansoprazole et leur elaboration
CN102219777B (zh) * 2010-04-19 2013-06-05 江苏豪森药业股份有限公司 制备雷贝拉唑钠的方法
CN101805327B (zh) * 2010-04-29 2012-11-21 郝志艳 一种雷贝拉唑钠化合物及其制法
WO2012027331A1 (fr) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions et procédés pour traiter ou prévenir un syndrome métabolique et des maladies et troubles associés
SG11201402796SA (en) 2011-12-16 2014-06-27 Atopix Therapeutics Ltd Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
CN104203938A (zh) 2012-01-21 2014-12-10 朱比兰特生命科学有限公司 用于制备2-吡啶基甲基亚硫酰基苯并咪唑、它们的类似物和光学活性对映体的方法
WO2014091450A1 (fr) 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Procédé pour la préparation de rabéprazole
CA2898362C (fr) 2013-01-15 2020-09-01 Ironwood Pharmaceuticals, Inc. Forme posologique orale a liberation prolongee a retention gastrique d'un agent sequestrant d'acide biliaire
CN103073536B (zh) * 2013-01-17 2015-06-24 丽珠医药集团股份有限公司 一种艾普拉唑的制备方法
CN103709141A (zh) * 2013-10-14 2014-04-09 寿光富康制药有限公司 雷贝拉唑钠的晶型及无定形形式
CN104119315B (zh) * 2014-05-21 2016-03-02 丽珠医药集团股份有限公司 一种雷贝拉唑钠的制备方法
RU2554735C1 (ru) * 2014-08-20 2015-06-27 Открытое Акционерное Общество "Татхимфармпрепараты" Фармацевтическая композиция, содержащая рабепразол натрия, и способ ее получения
US20180015118A1 (en) 2015-02-03 2018-01-18 Ironwood Pharmaceuticals, Inc. Methods of treating upper gastrointestinal disorders in ppi refractory gerd
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017145146A1 (fr) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprenant des inhibiteurs de la pompe à protons
CN106083705A (zh) * 2016-06-14 2016-11-09 上药康丽（常州）药业有限公司 2‑羟甲基‑4‑（甲氧基丙氧基）‑3‑甲基吡啶盐酸盐的制备方法
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN106349220A (zh) * 2016-08-25 2017-01-25 岳阳正昊化学科技有限公司 一种右旋雷贝拉唑钠的纯化方法
JP7044789B2 (ja) 2016-09-24 2022-03-30 ワシントン・ユニバーシティ Ｓａｒｍ１ ｎａｄアーゼ活性の阻害剤およびその使用
JP2022548785A (ja) 2019-09-24 2022-11-21 プロラクタ バイオサイエンス，インコーポレイテッド 炎症性疾患及び免疫疾患の治療のための組成物及び方法
JP2025532389A (ja) 2022-10-04 2025-09-29 ザビリュク，アルセニー 大動脈弁の石灰化の抑制

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
ZA825106B (en) * 1981-08-13 1983-04-27 Haessle Ab Novel pharmaceutical compositions
SE8300736D0 (sv) * 1983-02-11 1983-02-11 Haessle Ab Novel pharmacologically active compounds
GB8417171D0 (en) * 1984-07-05 1984-08-08 Beecham Group Plc Compounds
SE8404065D0 (sv) * 1984-08-10 1984-08-10 Haessle Ab Novel biologically active compounds
DE3509333A1 (de) * 1985-03-15 1986-09-18 Hoechst Ag, 6230 Frankfurt Substituierte benzimidazolderivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zubereitungen und ihre verwendung als magensaeuresekretionshemmer
JPH0674272B2 (ja) * 1986-11-13 1994-09-21 エーザイ株式会社 ピリジン誘導体及びそれを含有する潰瘍治療剤
DE4036908A1 (de) * 1990-11-20 1992-05-21 Ruetgers Pagid Ag Nutausbildung

Also Published As

Publication number Publication date
NL990015I2 (nl) 1999-09-01
HUT45524A (en) 1988-07-28
AU8113887A (en) 1988-05-19
DK131893D0 (da) 1993-11-24
HU198475B (en) 1989-10-30
ES2061471T5 (es) 1998-07-16
AU594836B2 (en) 1990-03-15
EP0268956B1 (fr) 1994-04-06
NO874477L (no) 1988-05-16
DE3752167T2 (de) 1998-06-25
NO170932C (no) 1992-12-30
KR880006229A (ko) 1988-07-22
EP0268956A2 (fr) 1988-06-01
NZ222488A (en) 1993-05-26
NL990015I1 (nl) 1999-08-02
DE3752167D1 (de) 1998-03-12
DE3752201D1 (de) 1998-08-13
ES2061471T3 (es) 1994-12-16
FI90544C (fi) 1994-02-25
EP0475456B1 (fr) 1998-02-04
NO170932B (no) 1992-09-21
EP0268956A3 (en) 1990-07-25
EP0654471B1 (fr) 1998-07-08
CN1018923B (zh) 1992-11-04
ATE163011T1 (de) 1998-02-15
FI874709A0 (fi) 1987-10-26
DK131893A (da) 1993-11-24
DE3789536T3 (de) 1998-08-20
DK575887D0 (da) 1987-11-03
DE3752201T2 (de) 1998-12-17
FI874709L (fi) 1988-05-14
DE19975035I2 (de) 2004-01-29
HK194296A (en) 1996-11-01
US5045552A (en) 1991-09-03
ES2112260T3 (es) 1998-04-01
EP0475456A1 (fr) 1992-03-18
US5840910A (en) 1998-11-24
JP2544567B2 (ja) 1996-10-16
US5998445A (en) 1999-12-07
NO874477D0 (no) 1987-10-27
FI90544B (fi) 1993-11-15
CA1265138A (fr) 1990-01-30
CN87107777A (zh) 1988-06-01
ES2118457T3 (es) 1998-09-16
EP0654471A1 (fr) 1995-05-24
EP0268956B2 (fr) 1998-04-15
DE3789536T2 (de) 1994-08-18
NO2000006I1 (no) 2000-09-18
JPH05247035A (ja) 1993-09-24
KR910003330B1 (ko) 1991-05-27
DE3789536D1 (de) 1994-05-11
DK575887A (da) 1988-05-14
ATE168111T1 (de) 1998-07-15
DK171024B1 (da) 1996-04-22

Similar Documents

Publication Publication Date Title
LU90396I2 (fr) Pariet principeactif: rabeprazole sodique rabeprazole et tout autre de ces sels pharmaceutiquement acceptable
CA2018960A1 (fr) Derives de la salicyladehyde et de l'acide salycilique et leurs analogues soufres, leur preparation et leur utilisation comme herbicides et bioregulateurs
IE810108L (en) IMIDAZO £1,2-a| PYRIDINES
MY109557A (en) Branched alkylamino derivatives of thiazole, processes for preparing them and pharmaceutical compositions containing them.
CS782686A2 (en) Method of benzimidazole derivatives production
MY101970A (en) Zwitterionic bicyclic compounds and their salts, solvates, hydrates and esters.
NO885655D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n-methylpyrrolidin- og fucitolderivater.
RU93045711A (ru) Нейролептические пергидро-1h-пиридо(1,2-a)пиразины, способ их получения, фармацевтическая композиция, способ лечения
YU50590A (sh) Supstituisani derivati azetidinil piridon karbonskih kiselina i postupak za njihovu izradu
MA21026A1 (fr) Derives de 4-(aroylamino) piperidinebutanamide, et leur procede de preparation
IL60217A0 (en) Paromomycin derivatives
DK165322C (da) Derivater af 4,5-dihydrooxazolyl-2-oe(2-pyridyl)-methylthioaa-benzimidazoler eller -thienoimidazoler, fremgangsmaade til fremstilling heraf og farmaceutiske praeparater indeholdende saadanne derivater
BR8400549A (pt) Derivados e sais inertes de hidroxido de aminopiridinios e processos de preparacao;e composicao farmaceutica
GR3026762T3 (en) Pyridine derivatives, pharmaceutical compositions comprising the same, the use of the same for the manufacture of medicaments having therapeutic or preventative value, and a process for preparing the same
NO923983L (no) Bisfenyletanderivater, fremgangsmaate for deres fremstilling og farmasoeytiske preparater derav
SE8300865L (sv) Mjoldrygealkaloider, forfarande for framstellning derav och dessa foreningar innehallande farmaceutiska kompositioner
FR2387979A1 (fr) Nouvelles 3-(thienyloxy) pyridines utiles comme medicaments et procedes pour leur preparation
RU92004439A (ru) Азотсодержащие тетрациклические соединения, способ их получения, применение и фармацевтическая композиция
TH4132A (th) เอสเทอร์ของ 7 เบต้า-(2-(2-อะมิโน-4-ไธอาซอลิ)-2-แอลเคโนอิลอะมิโน)-3-เซเฟม-4-คาร์บอกซิลิค แอซิด
SE8900725D0 (sv) Indolfoereningar och framstaellning daerav